Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications
E Jabbour, JE Cortes, HM Kantarjian - Cancer, 2008 - Wiley Online Library
The majority of patients with chronic‐phase (CP) chronic myeloid leukemia (CML) who are
treated with Bcr‐Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve …
treated with Bcr‐Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve …
Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications.
E Jabbour, JE Cortes, HM Kantarjian - Cancer, 2008 - europepmc.org
The majority of patients with chronic-phase (CP) chronic myeloid leukemia (CML) who are
treated with Bcr-Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve …
treated with Bcr-Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve …
Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications
E Jabbour, JE Cortes, HM Kantarjian - Cancer, 2008 - pubmed.ncbi.nlm.nih.gov
The majority of patients with chronic-phase (CP) chronic myeloid leukemia (CML) who are
treated with Bcr-Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve …
treated with Bcr-Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve …
[HTML][HTML] Molecular Monitoring in Chronic Myeloid Leukemia: Response to Tyrosine Kinase Inhibitors and Prognostic Implications
E Jabbour, JE Cortes, HM Kantarjian - Cancer, 2008 - ncbi.nlm.nih.gov
The majority of patients with chronic-phase (CP) chronic myeloid leukemia (CML) who are
treated with Bcr-Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve …
treated with Bcr-Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve …
Molecular monitoring in chronic myeloid leukemia: Response to tyrosine kinase inhibitors and prognostic implications
E Jabbour, JE Cortes, HM Kantarjian - Cancer, 2008 - mdanderson.elsevierpure.com
The majority of patients with chronic phase (CP) chronic myeloid leukemia (CML) who are
treated with Bcr-Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve …
treated with Bcr-Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve …
Molecular monitoring in chronic myeloid leukemia: Response to tyrosine kinase inhibitors and prognostic implications
E Jabbour, JE Cortes, HM Kantarjian - Cancer, 2008 - augusta.elsevierpure.com
The majority of patients with chronic phase (CP) chronic myeloid leukemia (CML) who are
treated with Bcr-Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve …
treated with Bcr-Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve …
[引用][C] Molecular Monitoring in Chronic Myeloid Leukemia: Response to Tyrosine Kinase Inhibitors and Prognostic Implications
E JABBOUR, JE CORTES, HM KANTARJIAN - Cancer, 2008 - pascal-francis.inist.fr
Molecular Monitoring in Chronic Myeloid Leukemia : Response to Tyrosine Kinase
Inhibitors and Prognostic Implications CNRS Inist Pascal-Francis CNRS Pascal and Francis …
Inhibitors and Prognostic Implications CNRS Inist Pascal-Francis CNRS Pascal and Francis …